290 related articles for article (PubMed ID: 28749311)
1. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte recovery after fingolimod discontinuation in patients with MS.
Nagy S; Kuhle J; Derfuss T
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801166
[TBL] [Abstract][Full Text] [Related]
3. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
Front Immunol; 2018; 9():2669. PubMed ID: 30524432
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
[TBL] [Abstract][Full Text] [Related]
6. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
7. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
[TBL] [Abstract][Full Text] [Related]
8. Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
Chiarini M; Sottini A; Bertoli D; Serana F; Caimi L; Rasia S; Capra R; Imberti L
Mult Scler; 2015 May; 21(6):726-34. PubMed ID: 25392322
[TBL] [Abstract][Full Text] [Related]
9. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
[TBL] [Abstract][Full Text] [Related]
10. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.
Johnson TA; Shames I; Keezer M; Lapierre Y; Haegert DG; Bar-Or A; Antel J
Clin Immunol; 2010 Oct; 137(1):15-20. PubMed ID: 20599429
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
Blumenfeld S; Staun-Ram E; Miller A
J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
Muls N; Dang HA; Sindic CJ; van Pesch V
PLoS One; 2014; 9(11):e113025. PubMed ID: 25411844
[TBL] [Abstract][Full Text] [Related]
13. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
Fragoso YD; Spelman T; Boz C; Alroughani R; Lugaresi A; Vucic S; Butzkueven H; Terzi M; Havrdova E; Horakova D; Granella F; Olascoaga J; Sánchez-Menoyo JL; Pucci E; Barnett M; Brooks JBB; Haartsen J;
Mult Scler Relat Disord; 2018 Jan; 19():105-108. PubMed ID: 29182993
[TBL] [Abstract][Full Text] [Related]
15. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
Hjorth M; Dandu N; Mellergård J
PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
17. High-Resolution Expression Profiling of Peripheral Blood CD8
Roch L; Hecker M; Friess J; Angerer IC; Koczan D; Fitzner B; Schröder I; Flechtner K; Thiesen HJ; Meister S; Winkelmann A; Zettl UK
Mol Neurobiol; 2017 Sep; 54(7):5511-5525. PubMed ID: 27631876
[TBL] [Abstract][Full Text] [Related]
18. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
19. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
Takahashi K
J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
[TBL] [Abstract][Full Text] [Related]
20. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.
Thomas K; Sehr T; Proschmann U; Rodriguez-Leal FA; Haase R; Ziemssen T
J Neuroinflammation; 2017 Feb; 14(1):41. PubMed ID: 28231856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]